Bangladesh Budget Boosts Health Sector Allocation, Experts Cautiously Optimistic

Bangladesh's latest budget has significantly increased allocation to the health sector, a move experts believe can reduce out-of-pocket expenses for citizens, particularly for non-communicable diseases like cancer. While the World Health Organization recommends at least 5% of GDP for health, Bangladesh has historically allocated less than 1%. This year marks a notable increase, surpassing the 1% threshold. Professor Dr. Syed Md. Akram Hossain, former member of the Health Sector Reform Commission, sees positive reflections of desired reforms in innovation, entrepreneurship, technology, and human resources. However, he stresses the need for bolder structural reforms, including strengthening primary healthcare, administrative decentralization, establishing a health commission, and developing digital health systems and health insurance, as recommended by the reform commission. He highlighted increased funding, emphasis on primary care, reduced taxes on essential medical supplies and raw materials, and encouragement for health technology as positive directions. These measures are expected to lower the cost of cancer drugs, dialysis equipment, and cardiac stents, benefiting the public. Cancer specialist Professor Dr. Parveen Shahida Akhter from Shanti Cancer Foundation welcomed the doubling of treatment allowances for six critical illnesses to 100,000 Taka, benefiting 65,000 patients. She noted that while this initiative is promising, cancer treatment remains largely inaccessible and expensive in Bangladesh. She emphasized the need for future efforts to make treatment more affordable and accessible, alongside increased public awareness and robust screening programs for early detection, which significantly improves outcomes and reduces costs. SM Mahmudul Hoque Pollab, Director at Beacon Pharmaceuticals, praised the government's initiative and highlighted the significant social impact of increased financial support, likening it to a 'humanitarian insurance.' He also pointed out the complete withdrawal of import duties on 51 new raw materials for Active Pharmaceutical Ingredients (APIs), including nine for cancer treatment, and reduced duties on other essential pharmaceutical inputs, which could lead to lower drug prices and enhance the competitiveness of Bangladesh's pharmaceutical industry globally. The budget's focus on reducing costs for critical treatments like cardiac surgery is also expected to attract patients from neighboring countries.